We are live on ! Find out more
CCCC icon

C4 Therapeutics
CCCC

75 hedge funds and large institutions have $743M invested in C4 Therapeutics in 2020 Q4 according to their latest regulatory filings, with 75 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

52.77% more ownership

Funds ownership: 0% → 52.77% (+53%)

Holders
75
Holders Change
+75
Holders Change %
–
% of All Funds
1.33%
Holding in Top 10
6
Holding in Top 10 Change
+6
Holding in Top 10 Change %
% of All Funds
0.11%
New
75
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$91.6M
2
CAM
Cormorant Asset Management
Massachusetts
+$72.2M
3
RI
RTW Investments
New York
+$62.3M
4
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
+$47.6M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$44.4M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$105M +$91.6M +3,158,566 New
CAM
2
Cormorant Asset Management
Massachusetts
$80M +$72.2M +2,490,065 New
RI
3
RTW Investments
New York
$68.7M +$62.3M +2,149,228 New
BCLSI
4
Bain Capital Life Sciences Investors
Massachusetts
$54.4M +$47.6M +1,642,209 New
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$49.4M +$44.4M +1,530,042 New
RCM
6
RA Capital Management
Massachusetts
$45.6M +$39.9M +1,377,569 New
Janus Henderson Group
7
Janus Henderson Group
United Kingdom
$40.4M +$37.6M +1,297,609 New
BlackRock
8
BlackRock
New York
$37.8M +$33M +1,139,591 New
Adage Capital Partners
9
Adage Capital Partners
Massachusetts
$29.5M +$25.8M +890,498 New
Fidelity Investments
10
Fidelity Investments
Massachusetts
$22.2M +$19.5M +671,287 New
Millennium Management
11
Millennium Management
New York
$18.4M +$16.1M +554,568 New
CC
12
Commodore Capital
New York
$15.9M +$14M +481,094 New
LGM
13
Logos Global Management
California
$15.8M +$13.9M +477,928 New
Vanguard Group
14
Vanguard Group
Pennsylvania
$15M +$13.1M +452,167 New
SFM
15
Sphera Funds Management
Israel
$14.6M +$12.9M +443,824 New
Invesco
16
Invesco
Georgia
$9.96M +$8.72M +300,542 New
SCM
17
Soleus Capital Management
Connecticut
$8.9M +$7.79M +268,548 New
ACH
18
ArrowMark Colorado Holdings
Colorado
$8.25M +$7.23M +249,149 New
DGM
19
Darwin Global Management
Jersey
$7.57M +$6.63M +228,595 New
EC
20
EcoR1 Capital
California
$6.63M +$5.8M +200,000 New
Geode Capital Management
21
Geode Capital Management
Massachusetts
$6.27M +$5.49M +189,251 New
Jennison Associates
22
Jennison Associates
New York
$5.74M +$5.03M +173,352 New
MS
23
Mizuho Securities
Japan
$5.61M +$4.91M +169,392 New
WP
24
Woodline Partners
California
$5.51M +$4.82M +166,323 New
State Street
25
State Street
Massachusetts
$5.47M +$4.79M +165,131 New
1
2 3

CCCC Hedge Fund Activity: Q4 2020 in Review

75 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q4 2020, worth a combined $743M.

Buyers outnumbered sellers: 75 funds opened new CCCC positions and 0 closed out — a net gain of 75 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $91.6M.

  • 75 institutional investors held C4 Therapeutics (CCCC) as of Q4 2020, up from 0 in Q3 2020.
  • Funds reported $743M of C4 Therapeutics stock for Q4 2020.
  • 75 funds opened new C4 Therapeutics positions in Q4 2020 and 0 closed out, a net change of +75 holders.
  • The largest C4 Therapeutics buyer in Q4 2020 was Perceptive Advisors, an estimated $91.6M added.

Based on aggregated 13F filings for Q4 2020.